Contemporary Initial Glucose-Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta-Analysis.
Gabriel Cavalcante Lima Chagas, Mayara Rios Leite Macedo Monteiro, Marina Loch Eira et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and Bayesian random-effects network meta-analysis compared initial glucose-lowering strategies in treatment-naïve adults with type 2 diabetes or after adequate washout. It included 20 randomized trials with 8947 participants. Against placebo, SGLT2 inhibitor plus metformin had the largest HbA1c reduction (mean difference [MD] -1.36%, 95% credible interval [CrI] -1.91 to -0.82), followed by GLP-1 receptor agonist or dual incretin agonist monotherapy (MD -1.25%, 95% CrI -1.68 to -0.83). Incretin monotherapy produced the greatest percentage weight reduction. Certainty across key comparisons was low or very low.
Key findings
- Compared with placebo, SGLT2 inhibitor plus metformin reduced HbA1c by MD -1.36%, 95% CrI -1.91 to -0.82.
- GLP-1 receptor agonist or dual incretin agonist monotherapy reduced HbA1c by MD -1.25%, 95% CrI -1.68 to -0.83, versus placebo.
- GLP-1 receptor agonist or dual incretin agonist monotherapy had the greatest body weight percentage reduction (MD -4.74%, 95% CrI -6.71 to -2.90).
- HbA1c target achievement and fasting plasma glucose reduction followed a similar pattern across strategies.
Why it matters
The analysis compares several contemporary options for initial treatment and suggests that glucose lowering and weight effects may differ by strategy. These outcomes can inform discussion of treatment priorities, while the low or very low certainty of evidence and indirect active-treatment comparisons mean that apparent differences should be interpreted cautiously.
What to keep in mind
Active-treatment comparisons were indirect, baseline HbA1c was higher in the SGLT2 inhibitor plus metformin group, and certainty was low or very low across key comparisons.